Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease

Archives of Internal Medicine

Volumn 167, Issue 21, 2007, Pages 2317-2322

  Gaba, Pinky D ^a   Haley, Connie ^a,b   Griffin, Marie R ^a,c   Mitchel, Ed ^a   Warkentin, Jon ^b   Holt, Erin ^b   Baggett, Pam ^b   Sterling, Timothy R ^a,d  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Health ^*  (United States)

^c GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG USE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; TUBERCULOSIS;

ADULT; AGED; CIPROFLOXACIN; FEMALE; FLUOROQUINOLONES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; OUTPATIENTS; PHARMACY; RISK FACTORS; TENNESSEE; TIME FACTORS; TUBERCULOSIS;

EID: 36549007398     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.167.21.2317     Document Type: Article

References (12)

1. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. Geneva, Switzerland: World Health Organization; 2006. Publication WHO/HTM/TB/2006 362.
2. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2004. Atlanta, GA: US Dept of Health and Human Services; 2005.
3. Blumberg HM, Burman WJ, Chaisson RE, et al; American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167(4):603-662.
4. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med. 2004;170(10):1131-1134.
5. Tuberculosis Research Center. Shortening short-course chemotherapy: a randomized clinical trial for treatment of smear-positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian J Tuberc. 2002;49:27-38.
6. Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med. 2005;118(3):259-268.
7. Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis. 2002;34(12):1607-1612.
8. Ginsburg AS, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis. 2003;37(11):1448-1452.
9. Ginsburg AS, Woolwine SC, Hooper N, et al. The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med. 2003;349(20):1977-1978.
10. Yoon YS, Lee HJ, Yoon HI, et al. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis. 2005;9(11):1215-1219.
11. Brodie D, Schluger NW. The diagnosis of tuberculosis. Clin Chest Med. 2005;26 (2):247-271, vi.
12. Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother. 1999;44(3):393-395.